Streetbeat News

Stock Prices

SHOO

Analysts have provided mixed reviews on Steven Madden (NASDAQ:SHOO) over the past quarter, with a range of ratings from bullish to indifferent. The average 12-month price target has increased to $45.5, reflecting a 1.68% rise. Key analysts have maintained or raised their ratings, indicating a positive outlook.

Portfolio Pulse from Benzinga Insights

July 25, 2024 | 12:02 pm

ZTS

Zoetis (NYSE:ZTS) has received mixed analyst ratings over the past three months, with all four analysts maintaining a 'Buy' rating but lowering their price targets. The average 12-month price target is now $205.25, down 4.98%. Zoetis has shown strong financial performance with a 9.5% revenue growth rate, a 27.35% net margin, and a high ROE of 11.91%. However, the company faces challenges with a high debt-to-equity ratio of 1.34.

Portfolio Pulse from Benzinga Insights

July 25, 2024 | 12:01 pm

TTD

In the last three months, 17 analysts have published ratings on Trade Desk (NASDAQ:TTD), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 4.47% to $107.53. Analysts have maintained or raised their ratings, reflecting positive expectations for the company's future performance.

Portfolio Pulse from Benzinga Insights

July 25, 2024 | 12:01 pm

ZVSA

ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) has selected obesity and related metabolic complications as the lead indication for its Inflammasome ASC Inhibitor IC 100. This decision marks a significant step in the company's development of first-in-class drugs for inflammatory and renal diseases.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 12:00 pm

ENVB

Enveric Biosciences (NASDAQ:ENVB) announced positive preclinical results for its non-hallucinogenic psychedelic drug candidate EB-003, which can be administered orally. The company plans to advance EB-003 to clinical trials by the end of 2025. Enveric also recently obtained a US patent for another drug candidate, EB-002, aimed at treating neurological disorders.

Portfolio Pulse from Nina Zdinjak

July 25, 2024 | 12:00 pm

AAPL

STM

TSLA

STMicroelectronics (STM), a supplier for Tesla (TSLA) and Apple (AAPL), reported a 25.3% YoY revenue decline for Q2 2024, beating analyst estimates. Despite beating EPS estimates, the stock plunged due to weak performance in industrial and automotive sectors. STM's outlook for Q3 and fiscal 2024 is below consensus estimates.

Portfolio Pulse from Anusuya Lahiri

July 25, 2024 | 11:59 am

ETHE

FETH

GBTC

IBIT

Bitcoin and Ethereum experienced significant price drops, with Bitcoin falling over 3% and Ethereum plunging below $3,200. The decline was linked to a broader market downturn affecting U.S. technology stocks. Ethereum ETFs saw substantial outflows, while Bitcoin ETFs recorded mixed inflows and outflows.

Portfolio Pulse from Murtuza Merchant

July 25, 2024 | 11:54 am

RTO

Rentokil Initial continues to expect organic revenue growth in North America within the guided 2-4% range for the full year, albeit at the lower end.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 11:48 am

CMMB

Chemomab Therapeutics has announced a private placement of $10 million, selling 4,188,867 American Depositary Shares (ADSs) and pre-funded warrants to purchase up to 3,908,300 ADSs. The purchase price is $1.235 per share, reflecting the average share price on Nasdaq for the last 4 trading days. The private placement is expected to close around July 26, 2024, subject to customary closing conditions.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 11:47 am

CMMB

Chemomab Therapeutics reported positive topline results from the Phase 2 SPRING trial of CM-101 for primary sclerosing cholangitis, achieving its primary endpoint with demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic effects.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 11:45 am